US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
ImmunityBio, Inc. - Common Stock
(NQ:
IBRX
)
10.29
+1.01 (+10.83%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunityBio, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
23
24
Next >
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
March 04, 2026
In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise...
Via
MarketMinute
Topics
Earnings
Economy
Dow, S&P 500, Nasdaq Futures Slip As Middle East War Fuels Oil Rally: Why MU, IBRX, BATL, DJT, SE Are On Traders’ Radar Today
↗
March 03, 2026
Investors are looking at earnings from Abercrombie & Fitch, Broadcom and Okta on Wednesday.
Via
Stocktwits
Topics
ETFs
Government
Stocks
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions
↗
March 03, 2026
To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites.
Via
Stocktwits
Topics
Earnings
Supply Chain
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook
↗
March 03, 2026
The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.
Via
Stocktwits
Topics
Artificial Intelligence
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend
↗
March 02, 2026
Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.
Via
Stocktwits
Topics
Artificial Intelligence
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
February 27, 2026
From
ImmunityBio
Via
Business Wire
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds
↗
February 26, 2026
Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday.
Via
Stocktwits
Topics
Government
IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial
↗
February 26, 2026
The company said it plans to submit a biologics license application by the fourth quarter of 2026.
Via
Stocktwits
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
February 26, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today
↗
February 26, 2026
Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Stocks
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally
↗
February 26, 2026
The filing comes ahead of ImmunityBio’s participation in the ASCO Genitourinary Cancers Symposium.
Via
Stocktwits
IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move
↗
February 24, 2026
Traders debated whether Trump could reference cancer priorities or FDA reform, with some betting a mention could spark another leg higher for IBRX.
Via
Stocktwits
Topics
Economy
Government
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth
↗
February 23, 2026
ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types.
Via
Stocktwits
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
↗
February 23, 2026
On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion.
Via
The Motley Fool
Topics
Stocks
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
February 23, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Check out the stocks that are attracting the most attention and driving market activity.
↗
February 23, 2026
Via
Chartmill
Why ImmunityBio Stock Is Soaring Again Today
↗
February 23, 2026
ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.
Via
The Motley Fool
These stocks are gapping in today's session
↗
February 23, 2026
Via
Chartmill
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market
↗
February 23, 2026
Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data
Via
Stocktwits
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
February 23, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today
↗
February 23, 2026
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Government
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough
↗
February 23, 2026
The chairman pointed to upcoming updates on IL-15’s long-studied role in cancer immunotherapy.
Via
Stocktwits
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts
↗
February 20, 2026
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time.
Via
Stocktwits
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
February 20, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today
↗
February 20, 2026
Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume.
Via
Stocktwits
Topics
ETFs
Economy
Government
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug
↗
February 20, 2026
Traders are closely watching positioning, as short interest hit a record 13.7% of the free float amid a jump in retail activity on Stocktwits this week.
Via
Stocktwits
Topics
Government
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
February 19, 2026
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...
Via
Finterra
Topics
Lawsuit
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries
↗
February 19, 2026
The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.
Via
Stocktwits
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
February 19, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today
↗
February 19, 2026
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.
Via
Stocktwits
Topics
ETFs
Economy
Government
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
23
24
Next >
